Vaccine Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Cancer Vaccine

IL-18-secreting fibroblasts prolong survival of tumor-bearing mice

"There is currently much interest in generating cytotoxic T lymphocyte (CTL) responses against tumor antigens as a therapy for cancer. In this study mouse fibroblasts (H-2^b) were genetically modified to express a costimulatory B7.1 and a mature interleukin (IL)-18, and then loaded with an ovalbumin (OVA) epitope (SIINFEKL, H-2K^b restricted) as a model antigen, and tested for the induction of OVA-specific CTLs in C57BL/6 mice (H-2^b). The genetically modified fibroblasts...

• View Other Issues of Vaccine Weekly
  
• View Other NewsRx Publications